For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Tourmaline Bio Inc’s stock clocked out at $16.68, down -6.61% from its previous closing price of $17.86. In other words, the price has decreased by -$6.61 from its previous closing price. On the day, 0.59 million shares were traded. TRML stock price reached its highest trading level at $17.94 during the session, while it also had its lowest trading level at $16.3.
Ratios:
To gain a deeper understanding of TRML’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 41.76 and its Current Ratio is at 41.76. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on December 15, 2023, initiated with a Buy rating and assigned the stock a target price of $41.
On November 17, 2023, Truist started tracking the stock assigning a Buy rating and target price of $43.Truist initiated its Buy rating on November 17, 2023, with a $43 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 29 ’24 when MCDADE MARK bought 100,000 shares for $32.50 per share. The transaction valued at 3,250,000 led to the insider holds 448,431 shares of the business.
Kulkarni Sandeep Chidambar bought 4,000 shares of TRML for $67,960 on Nov 17 ’23. The CEO now owns 729,735 shares after completing the transaction at $16.99 per share. On Nov 17 ’23, another insider, Thiara Parvinder, who serves as the Director of the company, bought 1,000 shares for $17.31 each. As a result, the insider paid 17,310 and bolstered with 83,782 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRML now has a Market Capitalization of 427783616 and an Enterprise Value of 353019776.
Stock Price History:
The Beta on a monthly basis for TRML is 2.40, which has changed by -0.30209208 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, TRML has reached a high of $48.31, while it has fallen to a 52-week low of $9.18. The 50-Day Moving Average of the stock is -49.85%, while the 200-Day Moving Average is calculated to be -39.80%.
Shares Statistics:
It appears that TRML traded 383.18K shares on average per day over the past three months and 313410 shares per day over the past ten days. A total of 20.34M shares are outstanding, with a floating share count of 15.46M. Insiders hold about 39.73% of the company’s shares, while institutions hold 37.16% stake in the company. Shares short for TRML as of 1711584000 were 663459 with a Short Ratio of 3.87, compared to 1709164800 on 779816.
Earnings Estimates
The current assessment of Tourmaline Bio Inc (TRML) involves the perspectives of 6 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.67 for the current quarter, with a high estimate of -$0.53 and a low estimate of -$0.96, while EPS last year was -$4.6. The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.5 and low estimates of -$1.
Analysts are recommending an EPS of between -$2.18 and -$3.86 for the fiscal current year, implying an average EPS of -$2.87. EPS for the following year is -$3.01, with 5 analysts recommending between -$0.62 and -$4.83.
